Accumulation of neurotoxic forms of amyloid-β proteins in senile plaques and hyperphosphorylated tau proteins in neurofibrillary tangles is a well-known pathophysiological hallmark of Alzheimer’s disease (AD). However, clinical trials with drugs targeting amyloid-β and tau have failed to demonstrate efficacy in treating AD. All currently FDA-approved anti-AD drugs have symptomatic effects only and are not able to cure this disease. This makes necessary to search for alternative therapeutic targets. Accumulating evidence suggests that systemic inflammation and related vascular dysfunction play important etiological roles in AD and precede its clinical manifestation. Therefore, novel therapeutic modalities targeted at these pathophysiological components of AD are intensively developed now. Phytochemicals such as resveratrol, curcumin, quercetin, genistein and catechins are promising anti-AD therapeutics due to their ability to affect major pathogenetic mechanisms of AD, including oxidative stress, neuroinflammation and mitochondrial dysfunction. The implementation of innovative approaches for phytochemical delivery, including the nanotechnology-based ones which enable to significantly enhance their oral bioavailability, would likely provide an opportunity to address many challenges of conventional anti-AD therapies. In this review, roles of inflammation and vascular dysregulation in AD are described and phytobioactive compound-based treatment strategies for AD are discussed.

老年斑中神经淀粉样β蛋白的神经毒性形式的积累和神经原纤维缠结中磷酸化tau蛋白的过度积累是阿尔茨海默氏病（AD）的著名病理生理学标志。然而，针对β-淀粉样蛋白和tau蛋白的药物的临床试验未能证明治疗AD的功效。目前所有FDA批准的抗AD药物仅具有症状作用，不能治愈该疾病。这使得必须寻找替代的治疗靶标。越来越多的证据表明，系统性炎症和相关的血管功能障碍在AD中起着重要的病因作用，并早于其临床表现。因此，针对AD的这些病理生理成分的新型治疗方式现在得到了广泛开发。植物化学物质，例如白藜芦醇，姜黄素，槲皮素，金雀异黄素和儿茶素因其影响AD的主要致病机制（包括氧化应激，神经炎症和线粒体功能障碍）的能力而成为有前途的抗AD疗法。实施创新的植物化学传递方法，包括基于纳米技术的方法，可以显着提高其口服生物利用度，这可能会为应对常规抗AD治疗的许多挑战提供机会。在这篇综述中，描述了炎症和血管失调在AD中的作用，并讨论了基于植物活性化合物的AD治疗策略。实施创新的植物化学传递方法，包括基于纳米技术的方法，可以显着提高其口服生物利用度，这可能会为应对常规抗AD治疗的许多挑战提供机会。在这篇综述中，描述了炎症和血管失调在AD中的作用，并讨论了基于植物活性化合物的AD治疗策略。实施创新的植物化学传递方法，包括基于纳米技术的方法，可以显着提高其口服生物利用度，这可能会为应对常规抗AD治疗的许多挑战提供机会。在这篇综述中，描述了炎症和血管失调在AD中的作用，并讨论了基于植物活性化合物的AD治疗策略。